Table 1.
Higher CD4 Count at Antiretroviral Therapy Initiation Is Associated with Viral Suppression (<40 Copies/mL) After 6 Months, N = 390
| Characteristic | Viral load <40 copies/mL n/N (%) | Bivariable analysisa |
Multivariable analysis |
||
|---|---|---|---|---|---|
| RRb(95% CI) | p | Adjusted RRc(95% CI) | p | ||
| Initiation CD4 count (cells/mm3) | |||||
| ≤200 | 67/93 (72.8) | 1 | 1 | ||
| 201–350 | 72/88 (81.8) | 1.12 (0.96–1.32) | .154 | 1.10 (0.94–1.28) | .245 |
| 351–500 | 85/92 (92.4) | 1.27 (1.10–1.46) | .001 | 1.24 (1.08–1.42) | .002 |
| >500 | 112/117 (95.7) | 1.32 (1.16–1.50) | .001 | 1.29 (1.13–1.46) | <.001 |
| Previous tuberculosis | |||||
| No | 291/330 (88.4) | 1 | 1 | ||
| Yes | 45/60 (74.6) | 0.84 (0.73–0.98) | .026 | 0.89 (0.77–1.02) | .094 |
a
In bivariable analysis there was no evidence of an association between viral suppression and potential confounders of gender, income, education, alcohol use, time from diagnosis to ART initiation, and travel time to clinic.
b
Adjusted for study arm.
c
Adjusted for study arm, age, and previous self-reported ART exposure.
ART, antiretroviral therapy; CI, confidence interval; RR, risk ratio.